CLINICAL_TRIALS
trial_result
· 2020-03-24
Clinical Trial Update: 12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia [Phase 2, Phase 3]
Summary
12-month open-label extension study of LCP-AtorFen in dyslipidemia completed; results posted in 2020.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Veloxis Pharmaceuticals | Conditions: Dyslipidemia | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2020-03-24